Evidence map›Paper›PMID 40389911›Full record

SynthesisBMC cancer2025

Venetoclax and hypomethylating agents versus induction chemotherapy for newly diagnosed acute myeloid leukemia patients: a systematic review and meta-analysis.

Yun Liu, Ying Zhang, Jinhong Gao, Lijuan Wang, Fang Xie, Chengtao Zhang, Peimin Mao, Jinsong Yan

Abstract readSystematic ReviewMeta-AnalysisComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yun Liu *Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, China.
Ying Zhang *Department of Laboratory Medicine, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Jinhong GaoDepartment of Hematology, The Second Hospital of Dalian Medical University, Dalian, China.
Lijuan WangDepartment of Hematology, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Fang XieDepartment of Hematology, The Second Hospital of Dalian Medical University, Dalian, China.
Chengtao ZhangDepartment of Hematology, The Second Hospital of Dalian Medical University, Dalian, China.
Peimin MaoDepartment of Laboratory Medicine, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China. mo.momin@hotmail.com.
Jinsong YanDepartment of Hematology, The Second Hospital of Dalian Medical University, Dalian, China. yanjsdmu@dmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVenetoclax with hypomethylating agents (VEN-HMAs) has shown inconsistent efficacy versus induction chemotherapy (IC) in newly diagnosed AML (ND-AML). Whether or not VEN-HMAs are of clinical benefit remains uncertain. We conducted this meta-analysis to evaluate the clinical benefit of VEN-HMAs versus IC in various subtypes of ND-AML.

methodsWe searched PubMed, Embase, Cochrane Library, and Web of Science databases up to 17 June 2024. The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). Data were extracted to perform meta-analysis or descriptive analysis. The random-effects model was used to calculate the effect sizes and 95% confidence interval (CI). Relative risk (RR) was used to estimate complete response (CR), CR/ complete response with incomplete blood count recovery (CRi), overall response rate (ORR), and 30-day mortality. Hazard ratio (HR) was used to evaluate overall survival (OS) data.

resultsFifteen retrospective cohort studies with 3809 participants were identified. Compared to the IC group, the pooled RR estimates for VEN-HMAs were 1.05 (95% CI 0.88-1.26, P = 0.591) for CR, 1.09 (95% CI 0.96-1.23, P = 0.195) for CR/ CRi, 0.84 (95% CI 0.60-1.18, P = 0.318) for ORR, and 0.86 (95% CI 0.50-1.49; P = 0.596) for 30-day mortality. VEN-HMAs prolonged the OS advantage in the ND-AML population (HR = 0.80, 95% CI 0.66-0.97, P = 0.025), and was demonstrated in patients with nucleophosmin 1 (NPM1) mutation (HR = 0.64, 95% CI 0.44-0.92, P = 0.017). In AML patients with RUNX1::RUNX1T1 cytogenetic abnormalities, the pooled ORR was lower in the VEN-HMAs group (RR = 0.44, 95% CI 0.28-0.69, P < 0.001), but OS was of no significantly different (HR = 1.30, 95% CI 0.52-3.26,P = 0.58). However, only 2 studies were available and the results should be taken with caution. OS benefit was similar in other subgroup analyses based on cytogenetic risk, age, and AML type (de novo, secondary, treatment-related or prior therapy for myeloid disease cohort).

conclusionCompared with the IC group, VEN-HMAs improved OS in ND-AML, especially in the NPM1 mutation subgroup (HR = 0.64), ensured the efficacy of CR, CR/CRi and ORR, without increasing 30-day mortality, necessitating further head-to-head randomized controlled trials (RCTs).

trial registrationThis trial was registered with PROSPERO ( www.crd.york.ac.uk/prospero/ ) on 13 July 2024, the registration number is CRD42024560585.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicInduction ChemotherapyLeukemia, Myeloid, AcuteSulfonamidesDecitabineHumansNucleophosminBridged Bicyclo Compounds, HeterocyclicDecitabineNPM1 protein, humanNucleophosminSulfonamidesvenetoclaxAcute myeloid leukemiaHypomethylating agentsIntensive chemotherapyMeta-analysisSurvivalVenetoclax

Identifiers

PMID40389911
PMCPMC12090470

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.